🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Düsseldorf
Clinical trial register · Germany

Clinical Trials in Düsseldorf, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Heinrich-Heine University, Duesseldorf43 AstraZeneca20 Merck Sharp & Dohme LLC13 Hoffmann-La Roche13 Janssen Research & Development, LLC8
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Düsseldorf

420 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
DrugsDatopotamab deruxtecan·Durvalumab·Nab-paclitaxel·Gemcitabine
AstraZeneca
Phase 3
625
Düsseldorf, Essen, Georgsmarienhütte, Hamburg, Hanover, Heidelberg, Heilbronn, Leipzig
2023-11-23
Recruiting
Pretreatment to Promote Graft Survival After Subsequent High-risk Corneal Transplantation [CrossCornealVision]
NCT05870566Corneal Transplantation
Claus Cursiefen
Not applicable
110
München, Cologne, Düsseldorf, Homburg, Berlin, Freiburg im Breisgau, Rostock
2023-11-20
Active, closed
The PEERLESS II Study
NCT06055920Pulmonary Embolism
Inari Medical
Not applicable
1,200
Augsburg, Bad Krozingen, Berlin, Cologne, Dresden, Düsseldorf, Essen, Frankfurt
2023-11-17
Active, closed
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
NCT06055725Spasticity as Sequela of Stroke
Ipsen
Observational
1,057
Altenburg, Berlin, Dresden, Düsseldorf, Essen, Kiel, Lübeck, Mainz
2023-11-01
Recruiting
SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
NCT06054035Type2diabetes, PreDiabetes, Renal Failure
DrugDapagliflozin
University Hospital Tuebingen
Phase 4
170
Berlin, Dresden, Düsseldorf, Heidelberg, Leipzig, Lübeck, München, Tübingen
2023-10-26
Active, closed
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
NCT05949684Myelodysplastic Syndromes
DrugsEpoetin Alfa·Reblozyl·Luspatercept
Bristol-Myers Squibb
Phase 3
402
Erding, Münster, Koblenz, Leipzig, Jena, Berlin, Düsseldorf, Lübeck
2023-10-24
Recruiting
Smart Monitoring Assessing Spasticity-related Health
NCT06937723Multiple Sclerosis
Heinrich-Heine University, Duesseldorf
Observational
46
Düsseldorf
2023-10-19
Active, closed
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115Plaque Psoriasis
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
684
Bad Bentheim, Berlin, Bonn, Dresden, Dülmen, Düsseldorf, Frankfurt am Main, Freiburg im Breisgau
2023-10-12
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240Alopecia Areata
DrugUpadacitinib
AbbVie
Phase 3
1,500
Munich, Bad Bentheim, Düsseldorf, Münster, Lübeck, Berlin
2023-10-11
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
5,511
Aachen, Berlin, Cologne, Darmstadt, Deggendorf, Dessau, Düsseldorf, Essen
2023-10-05
Active, closed
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080Large B-Cell Lymphoma
DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone
Hoffmann-La Roche
Phase 3
1,130
Berlin, Brandenburg an der Havel, Chemnitz, Cologne, Düsseldorf, Erlangen, Essen, Frankfurt
2023-09-18
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Minden, Mainz, Cologne, Düsseldorf, Tübingen
2023-09-13
Active, closed
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
NCT05869955Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
DrugsZola-cel·Tocilizumab·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
270
Würzburg, Cologne, Leipzig, Magdeburg, Berlin, Düsseldorf, Erlangen
2023-09-13
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239Metastatic Breast Cancer
DrugsPhesgo·Inavolisib
Hoffmann-La Roche
Phase 3
230
Amberg, Berlin, Bottrop, Düsseldorf, Erfurt, Erlangen, Freiburg im Breisgau, München
2023-09-08
Recruiting
Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer
NCT06133543Germ Cell Tumor, Seminoma, Nonseminomatous Germ Cell Tumor
Heinrich-Heine University, Duesseldorf
Not applicable
44
Düsseldorf
2023-09-06
Recruiting
The ReTAVI Prospective Observational Registry
NCT05601453Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction
Institut für Pharmakologie und Präventive Medizin
Observational
250
Bad Krozingen, Bad Nauheim, Bad Oeynhausen, Berlin, Bochum, Düsseldorf, Essen, Munich
2023-09-05
Recruiting
PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND
NCT06144736Seminoma
Heinrich-Heine University, Duesseldorf
Phase 2
60
Düsseldorf
2023-08-28
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200Colonic Neoplasms, Neoplasms, Colon
DrugsCapeox·Dostarlimab·Folfox
GlaxoSmithKline
Phase 3
892
Berlin, Düsseldorf, Frankfurt, Halle, Lübeck, Mannheim, München
2023-08-01
Recruiting
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema
NCT05890677Lymphedema, Breast Cancer
University Hospital, Basel, Switzerland
Not applicable
280
Bochum, Düsseldorf, Erlangen, Essen, Frankfurt, Freiburg im Breisgau, Ludwigshafen am Rhein, Nuremberg
2023-07-14
Recruiting
Mechanisms Of Disease Progression in Aortic Stenosis - the MODAS Study
NCT05851209Aortic Stenosis, Imaging, Pathogenesis, Disease Progression
Heinrich-Heine University, Duesseldorf
Observational
938
Bonn, Cologne, Düsseldorf
2023-07-01
Recruiting
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
NCT05807932Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
DrugsMycophenolate Mofetil·Ara-C·Tacrolimus·Venetoclax
Heinrich-Heine University, Duesseldorf
Phase 1/2
38
Aachen, Düsseldorf, Cologne, Frankfurt, Jena, München
2023-06-26
Recruiting
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
NCT05427370Coronary Artery Disease, Heart Failure Systolic
Sunnybrook Health Sciences Centre
Not applicable
754
Düsseldorf, Leipzig
2023-06-22
Active, closed
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182Hidradenitis Suppurativa
DrugUpadacitinib
AbbVie
Phase 3
1,328
Freiburg im Breisgau, Erlangen, Regensburg, Würzburg, Frankfurt am Main, Bad Bentheim, Bramsche, Düsseldorf
2023-06-21
Active, closed
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
NCT05583552Myelodysplastic Syndromes, Acute Myeloid Leukemia
DrugImetelstat sodium
GCP-Service International West GmbH
Phase 2
46
Düsseldorf, Jena, Leipzig, München
2023-06-05
Not yet open
Mesopancreas Study in Pancreatic Cancer
NCT05895214PDAC, Pancreatoduodenectomy, Margin, Resection, Surgery
Heinrich-Heine University, Duesseldorf
Observational
500
Düsseldorf
2023-06-01
Active, closed
Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC
NCT05433116Head and Neck Squamous Cell Carcinoma
DrugsLenvatinib·Keytruda·Pembrolizumab
Universität des Saarlandes
Phase 2
50
Ulm, Augsburg, Erlangen, Regensburg, Frankfurt am Main, Giessen, Düsseldorf, Homburg
2023-05-25
Recruiting
Liquid Biopsy in Paraneoplastic Neurological Syndromes
NCT07491328Paraneoplastic Neurological Syndromes
Heinrich-Heine University, Duesseldorf
Observational
60
Düsseldorf
2023-05-20
Recruiting
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
NCT05319730Esophageal Squamous Cell Carcinoma
DrugsMK-4830·Steroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 1/2
230
Erdgeschoss, Frankfurt am Main, Düsseldorf, Berlin
2023-05-16
Recruiting
Multicenter Glaucoma Study Investigating Standalone Canaloplasty
NCT05786196Primary Open Angle Glaucoma
Nova Eye, Inc.
Not applicable
86
Düsseldorf
2023-05-09
Active, closed
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
NCT05876754Cholangiocarcinoma
DrugIvosidenib
Servier Affaires Médicales
Phase 3
299
Berlin, Dresden, Düsseldorf, Frankfurt, Freiburg im Breisgau, Hanover, München
2023-05-03
Active, closed
IMPACT EU Post-Market Clinical Follow-Up Study
NCT05756751Left Ventricular Dysfunction
Abiomed Inc.
Not applicable
123
Heidelberg, Aachen, Düsseldorf, Essen, Mainz, Halle, Kiel, Berlin
2023-04-27
Recruiting
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Weill Medical College of Cornell University
Not applicable
2,300
Bad Krozingen, Bad Oeynhausen, Berlin, Duisburg, Düsseldorf, Erlangen, Essen, Frankfurt
2023-04-17
Active, closed
A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction
NCT07304843Primary Biliary Cholangitis (PBC)
Umecrine Cognition AB
Phase 1/2
84
Düsseldorf, Leipzig
2023-04-14
Active, closed
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
NCT05723562Neoplasms, Rectal
DrugDostarlimab
GlaxoSmithKline
Phase 2
154
Berlin, Dresden, Düsseldorf, Frankfurt, München
2023-04-03
Active, closed
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
NCT05798156Lymphoma, Large B-Cell, Diffuse
DrugsPolatuzumab Vedotin·Glofitamab·Obinutuzumab·Rituximab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
125
Magdeburg, Berlin, Bochum, Chemnitz, Düsseldorf, Erlangen, Essen, Halle
2023-03-20
Recruiting
Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia
NCT05366218ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse, Acute Lymphocytic Leukemia Refractory
DrugTafasitamab
University Hospital Tuebingen
Phase 1/2
20
Freiburg im Breisgau, Tübingen, Ulm, München, Hamburg, Düsseldorf, Berlin, Essen
2023-03-08
Active, closed
A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice.
NCT05637112Systemic Lupus Erythematosus
AstraZeneca
Observational
551
Heidelberg, Erlangen, Bad Bramstedt, Schleswig-Holstein, Greifswald, Cologne, D Sseldorf, Herne
2023-02-27
Active, closed
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
NCT05741476Allergy, Peanut
DBV Technologies
Phase 3
600
Düsseldorf, Frankfurt, Ulm
2023-02-21
Active, closed
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
NCT05605899High-risk Large B-cell Lymphoma (LBCL)
DrugsAxi-cel·Axicabtagene Ciloleucel·Vincristine·Doxorubicin
Kite, A Gilead Company
Phase 3
300
Berlin, Bonn, Düsseldorf, Erlangen
2023-02-10
Recruiting
AI Screening for Diabetic Retinopathy
NCT05704491Diabetes Mellitus
West German Center of Diabetes and Health
Observational
100
Düsseldorf
2023-01-30
Active, closed
Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve
NCT05397106Hydrocephalus, Hydrocephalus in Children, NPH (Normal Pressure Hydrocephalus), IIH - Idiopathic Intracranial Hypertension
Integra LifeSciences Corporation
Observational
160
Dortmund, Düsseldorf, Essen, Freiburg im Breisgau, Stuttgart
2023-01-24
Recruiting
Home-based Gait and Balance Training in Patients With Movement Disorders
NCT06617884Ataxia, Parkinson Disease
Forschungszentrum Juelich
Not applicable
80
Düsseldorf
2023-01-04
Recruiting
DERIVO® 2heal® Study: Clinical Safety and Efficacy of the DERIVO® 2heal® Embolisation Device
NCT05543447Intracranial Aneurysm, Flow Diverter
Acandis GmbH
Observational
158
Augsburg, Berlin, Bremerhaven, Cologne, Dresden, Düsseldorf, Essen, Frankfurt am Main
2022-12-15
Recruiting
Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
NCT03994471End Stage Renal Disease
Iperboreal Pharma Srl
Phase 3
170
Düsseldorf
2022-12-14
Active, closed
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
NCT05469737Myelodysplastic Syndromes
DrugAzacitidine
Bristol-Myers Squibb
Phase 2/3
230
Duisburg, Düsseldorf, Leipzig, Dresden, Hamburg, Mutlangen
2022-12-14
Recruiting
GMMG Multiple Myeloma Registry
NCT07111884Multiple Myeloma
Prof. Dr. Hartmut Goldschmidt
Observational
999
Berlin, Bielefeld, Bochum, Bonn, Chemnitz, Cologne, Darmstadt, Düsseldorf
2022-12-08
Recruiting
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
NCT05695508Multiple Myeloma
DrugsRamantamig·Talquetamab·Teclistamab·Bortezomib
University of Heidelberg Medical Center
Phase 2
160
Berlin, Chemnitz, Dresden, Düsseldorf, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel
2022-12-01
Active, closed
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
NCT05588843Colitis Ulcerative
Sanofi
Phase 2
187
Düsseldorf, Fulda, Kiel, Ludwigshafen, Ulm
2022-11-25
Active, closed
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3
260
Berlin, Düsseldorf, München, Würzburg
2022-11-21
Active, closed
RESPONDER-HF Trial
NCT05425459Heart Failure, Heart Failure, Diastolic
Corvia Medical
Not applicable
750
Bad Krozingen, Bad Nauheim, Berlin, Cologne, Dresden, Düsseldorf, Freiburg im Breisgau, Göttingen
2022-11-17
Recruiting
Further Evaluation of Safety and Performance of the NEXUS Aortic Arch Stent Graft System and the Custom-Made NEXUS Multibranch™ Aortic Arch Stent Graft System
NCT05636527AAT9
Endospan Ltd.
Observational
70
Bernau bei Berlin, Düsseldorf, Berlin, Bonn
2022-11-09
By invitation
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
NCT05374291Kidney Disease, Chronic, Renal Transplant Failure, Heart Failure, Kidney Failure
DrugDapagliflozin
University Medical Center Groningen
Phase 3
1,750
Berlin, Düsseldorf, Erlangen, Halle, Hamburg, Hanover, Heidelberg, Heilbronn
2022-11-08
Active, closed
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
NCT05490446Myelodysplastic Syndromes
DrugTebapivat
Agios Pharmaceuticals, Inc.
Phase 2
87
Hanover, Düsseldorf, Leipzig
2022-11-07
Active, closed
Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients
NCT05582902MDS, MDS/MPN
University of Leipzig
Observational
60
Berlin, Chemnitz, Dresden, Düsseldorf, Jena, Leipzig, Mainz, Mannheim
2022-10-11
Recruiting
VRAP-Heart - Virtual Reality Assisted Patient Empowerment for Interventions in Structural Heart Disease
NCT05552352Severe Aortic Valve Stenosis
Heinrich-Heine University, Duesseldorf
Not applicable
300
Düsseldorf, Cologne
2022-10-05
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole
Eli Lilly and Company
Phase 3
8,000
Augsburg, Berlin, Bottrop, Cologne, Dessau, Donauwörth, Dortmund, Düsseldorf
2022-10-04
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085Relapsed or Refractory Multiple Myeloma
DrugsMezigdomide·Velcade·Pomalidomide·Bortezomib
Celgene
Phase 3
810
München, Traunstein, Weiden, Marburg, Hanover, Bonn, Düsseldorf, Kiel
2022-09-20
Active, closed
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
DrugSonrotoclax
BeOne Medicines
Phase 1/2
125
Cologne, Düsseldorf
2022-09-05
By invitation
Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis
NCT04814693Acute Pancreatitis, Necrosis; Pancreas, Acute (Infectious)
Erasmus Medical Center
Not applicable
60
Düsseldorf, Frankfurt
2022-09-02
Recruiting
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms
DrugsElacestrant·Abemaciclib
Stemline Therapeutics, Inc.
Phase 1/2
73
Bayreuth, Cologne, Dresden, Düsseldorf, Erlangen, Hanover, Leipzig, Worms
2022-08-31
Active, closed
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
NCT05271409Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
DrugSatralizumab
Hoffmann-La Roche
Phase 3
132
Berlin, Bochum, Datteln, Düsseldorf, Mannheim, Munich
2022-08-30
Recruiting
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
NCT05477563Beta-Thalassemia, Thalassemia, Hematologic Diseases, Genetic Diseases, Inborn
DrugExa-cel
Vertex Pharmaceuticals Incorporated
Phase 3
26
Düsseldorf
2022-08-02
Active, closed
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
NCT05033756Malignant Neoplasm of Breast, Breast Cancer
DrugsOlaparib·Keytruda·Pembrolizumab
Institut fuer Frauengesundheit
Phase 2
11
Tübingen, Ulm, Erlangen, Bottrop, Düsseldorf, Berlin
2022-07-30
Active, closed
Noninterventional Study Evaluating Parkinson's Disease Diary Use
NCT05363046Parkinson's Disease
BlueRock Therapeutics
Observational
194
Wolfach, Munich, Würzburg, Marburg, Düsseldorf, Rostock, Tübingen
2022-07-29
Recruiting
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)
NCT04165486Multiple System Atrophy
Ionis Pharmaceuticals, Inc.
Phase 1
40
Ulm, Düsseldorf, Göttingen, Hanover, Marburg, München
2022-07-21
Active, closed
STAR-LIFE: a Post-market Registry on MINIject
NCT05269680Open Angle Glaucoma
iSTAR Medical
Observational
320
Bochum, Düsseldorf, Hamburg, Kiel, Lübeck, Ulm
2022-07-20
Recruiting
Post COVID-19 Condition
NCT05531773COVID-19
Euresist Network GEIE
Observational
2,300
Düsseldorf
2022-07-01
Recruiting
International Wilson's Disease Patient Registry (iWilson Registry)
NCT05239858Wilson's Disease
Orphalan
Observational
500
Berlin, Düsseldorf, Hanover, Leipzig
2022-06-29
Active, closed
Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome
NCT05382156Endogenous Cushing's Syndrome
DrugOsilodrostat
RECORDATI GROUP
Observational
206
Berlin, Cologne, Düsseldorf, Frankfurt, Hamburg, Munich, Oldenburg, Würzburg
2022-06-13
Recruiting
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
NCT05280509Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis
DrugRuxolitinib
Telios Pharma, Inc.
Phase 1/2
70
Düsseldorf, Halle
2022-06-09
Recruiting
Optimizing Quality of Life by Improved Patient Expectation Following Atrial Fibrillation Catheter Ablation
NCT05557526Atrial Fibrillation
Evangelical Hospital Düsseldorf
Not applicable
60
Düsseldorf, Essen
2022-06-09
Active, closed
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
NCT05356195Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases
DrugExa-cel
Vertex Pharmaceuticals Incorporated
Phase 3
16
Düsseldorf
2022-05-03
Active, closed
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 3
1,300
Tübingen, Ulm, Bayreuth, Munich, Westerstede, Düsseldorf, Chemnitz, Leipzig
2022-05-03
Active, closed
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT05329649Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies
DrugExa-cel
Vertex Pharmaceuticals Incorporated
Phase 3
13
Düsseldorf
2022-05-02
Active, closed
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT05028348Multiple Myeloma
DrugsElotuzumab·Selinexor·Pomalidomide·Dexamethasone
European Myeloma Network B.V.
Phase 3
117
Chemnitz, Düsseldorf, Greifswald, Hamburg
2022-04-19
Recruiting
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
NCT05197192Chronic Lymphocytic Leukemia
DrugsVenclyxto·Venclexta·Acalabrutinib·Obinutuzumab
German CLL Study Group
Phase 3
202
Bad Saarow, Berlin, Bremen, Cologne, Dortmund, Düsseldorf, Eschweiler, Essen
2022-04-19
Recruiting
Health Care Workers Cohort Study in the EuCARE Project (EuCARE-HCW)
NCT05534009COVID-19
Euresist Network GEIE
Observational
1,800
Düsseldorf
2022-04-01
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
DrugsTremelimumab·Lenvatinib·Durvalumab
AstraZeneca
Phase 3
760
Bonn, Chemnitz, Dresden, Düsseldorf, Frankfurt, Göttingen, Hamburg, Hanover
2022-03-28
Active, closed
TRICuspid Intervention in Heart Failure Trial
NCT04634266Heart Failure Attributable to Severe Tricuspid Regurgitation
LMU Klinikum
Not applicable
360
Bad Oeynhausen, Berlin, Bernau, Bonn, Bremen, Cologne, Dortmund, Düsseldorf
2022-03-25
Active, closed
Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation
NCT05269862Parkinson Disease
Abbott Medical Devices
Not applicable
100
Tübingen, Düsseldorf, Mainz
2022-03-24
Active, closed
Prostate Imaging Using MRI +/- Contrast Enhancement
NCT04571840Prostate Cancer
University College, London
Not applicable
500
Düsseldorf, Essen, Frankfurt, Hamburg
2022-03-22
Active, closed
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
NCT05248646Immunoglobulin A Nephropathy
DrugSibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Frankfurt am Main, Düsseldorf, Mainz, Dresden
2022-03-15
Active, closed
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728Carcinoma, Renal Cell
DrugsBelzutifan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,800
Singen, Tübingen, Munich, Aachen, Bonn, Düsseldorf, Essen, Münster
2022-03-15
Recruiting
Menopause Related Influences on Leukocyte Distribution, Monocyte Function and Platelet Reactivity
NCT05985447Arteriosclerosis, Acute Myocardial Infarction, Cardiovascular Events, Menopause
Heinrich-Heine University, Duesseldorf
Observational
180
Düsseldorf
2022-03-07
Active, closed
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
NCT05153226Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation, AML, MDS
DrugCyclophosphamide
DKMS gemeinnützige GmbH
Phase 3
640
Aachen, Augsburg, Chemnitz, Cologne, Dortmund, Dresden, Düsseldorf, Essen
2022-03-02
Recruiting
Hospitalised COVID-19 Patients Cohort Study in the EuCARE Project
NCT05463380COVID-19
Euresist Network GEIE
Observational
22,000
Düsseldorf
2022-02-23
Active, closed
Clinical Impact of the IBox As an Early Intervention TooL
NCT05112315Kidney Diseases, Kidney Disease, Chronic, Kidney Transplant Rejection, Kidney Transplant; Complications
Predict4Health
Not applicable
507
Düsseldorf, Hamburg
2022-02-18
Recruiting
REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs
NCT05223413Anthracycline-induced Cardiac Toxicity, Lymphoma
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Not applicable
608
Düsseldorf
2022-01-18
Recruiting
The "Global Paradise System" Registry
NCT05027685Hypertension
ReCor Medical, Inc.
Observational
3,000
Ahrweiler, Bad Krozingen, Berlin, Coburg, Cologne, Detmold, Dresden, Düsseldorf
2022-01-13
Recruiting
5-year Follow up Study on the Comparative Performance of Two-piece Zirconia and Titanium Implants
NCT05326880Dental Implants, Single Tooth Lost, Dental Implant Failed
The University of Hong Kong
Not applicable
60
Düsseldorf
2022-01-03
Active, closed
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
NCT05182385ALL, Recurrent, Adult
DrugsVenclyxto·Blinatumomab·Venetoclax
Goethe University
Phase 1/2
30
Tübingen, Ulm, Frankfurt am Main, Dresden, Berlin, Cologne, Düsseldorf, Erlangen
2021-12-15
Active, closed
From the Emergency Department Directly to Ablation of Atrial Fibrillation Study
NCT05294445Atrial Fibrillation (AF)
Asklepios proresearch
Not applicable
350
Bad Nauheim, Berlin, Cologne, Düsseldorf, Frankfurt, Giessen, Hamburg, Hamburg-Nord
2021-12-15
Active, closed
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
NCT04954859Hepatitis B
DrugBepirovirsen
GlaxoSmithKline
Phase 2
360
Düsseldorf, Berlin, Frankfurt am Main, Hamburg
2021-12-14
Active, closed
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
DrugsDocetaxel·Paclitaxel·Bevacizumab·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
643
Erlangen, Bonn, Düsseldorf, Krefeld, Saarbrücken, Dresden, Leipzig, Berlin
2021-12-13
Recruiting
Mitochondrial Substrate Utilization in the Diabetic Human Heart
NCT05958706Heart Failure, Type2diabetes, Insulin Resistance, Mitochondrial Diseases
Heinrich-Heine University, Duesseldorf
Observational
500
Düsseldorf
2021-12-01
Recruiting
A Planned Study at Multiple Sites is Being Done to Compare the Results of Two Types of Trifocal Toric Intraocular Lenses Used in Cataract Surgery
NCT07232615Presbyopia Correction, Astigmatism, Cataract
Biotech Healthcare Holding Gmbh
Not applicable
138
Düsseldorf, Greven, Rheine
2021-11-22
Recruiting
High Dose Steroids in Children With Stroke
NCT04873583Paediatric Stroke
DrugsSolu-Medrol·Prednisolone·Methylprednisolone
Insel Gruppe AG, University Hospital Bern
Phase 3
70
Freiburg im Breisgau, München, Düsseldorf, Münster, Berlin, Hanover
2021-11-16
Active, closed
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
NCT04994717Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
DrugBlinatumomab
Amgen
Phase 3
303
Augsburg, Berlin, Dresden, Düsseldorf, Heidelberg, Jena, Kiel, München
2021-11-02
Recruiting
Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies
NCT06586177Relapsing-remitting Multiple Sclerosis
Heinrich-Heine University, Duesseldorf
Observational
100
Düsseldorf
2021-10-27
Recruiting
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT04929223Metastatic Colorectal Cancer
DrugsDivarasib·Tiragolumab·Inavolisib·Folfiri
Hoffmann-La Roche
Phase 1
542
Berlin, Bochum, Dresden, Düsseldorf, Hamburg, Heilbronn, München, Ulm
2021-10-22
Rows per page Showing 201–300 of 420
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/d-sseldorf?page=3

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 420 of those studies with a site in Düsseldorf.

How many clinical trials are recruiting in Düsseldorf?

240 of the 420 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 20 have not yet opened recruitment, 153 are active but closed to new participants, and 7 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.